Related Experiment Video
Updated: Jul 20, 2026

Effects of Mindfulness Training Combined with Tai Chi in Patients with Diabetic Peripheral Neuropathy
Published on: July 14, 2023
PDE5 inhibitors in diabetic peripheral neuropathy
1Good Hope Hospital, Sutton Coldfield, UK. geoff.hackett@virgin.net
Abstract:
Peripheral neuropathy is the most common complication of diabetes. This paper reviews the case histories of five patients with diabetic peripheral neuropathy or severe peripheral vascular disease who reported improvement in their symptoms when treated with regular or daily dosing with phosphodiesterase type 5 inhibitors (PDE5Is). These patients had been previously treated with PDE5Is for erectile dysfunction (ED) and not responded to on-demand therapy with a PDE5I at maximal recommended dose. This improvement is likely to be due to the known benefit of these drugs on endothelial dysfunction via an improvement of blood supply to the vasa nervorum. These cases suggest that further research is indicated to evaluate the potential use of PDE5Is in the treatment and prevention of diabetic peripheral neuropathy, particularly as these drugs are already licensed to treat ED, which occurs in around 50% of male diabetics.
Related Concept Videos
Diabetic Neuropathy
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Dipeptidyl Peptidase 4 Inhibitors
Diabetic Foot Ulcer
Diabetic Retinopathy
Diabetic Nephropathy